Nyheter

CELLINK and Ossiform look to capitalize on synergies and bring to the market a highly functional bioink for bone-based research. The partnership has scope for additional materials, including clinical grade bioinks.

(November 30, Gothenburg – Odense): CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels.

Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on the overall quality of life. A recent report by the WHO put the global disease burden of musculoskeletal conditions at 1.71 billion people globally, and the biggest contributing condition to years living with disability. While the advent of personalized bone implants provides a treatment pathway that can drastically improve the quality of life for many of these patients. Being able to do this is in a cost effective and scalable manner remains a significant priority.

“Bone has been an application area that CELLINK has focused greatly on in the past and we look forward to supporting our customers by providing Ossiform’s novel material, tailored for bone-based research as a printable bioink. We firmly believe this synergistic approach will lead to a tremendous outcome for the entire industry,” said Cecilia Edebo, CEO CELLINK.

“At Ossiform We Print Bone™ and soon we expect to obtain an FDA approval for our first P3D Bone implant. Currently we are providing bone products for research use only, and from today we will also provide our unique bioink to CELLINK. We are very excited to be working alongside CELLINK, leveraging their leading position in the 3D bioprinting Industry while also keeping close communication on future material and devices that can support our long-term vision of producing patient matched bone implants,” said Thea Wulff Olesen, CEO Ossiform.

CELLINK and Ossiform will be at the American Society of Cell biology conference, taking place in Boston from December 2nd to 6th, to present Ossi Ink and demonstrate the versatility that this material will provide researchers.

For further information, please contact:

Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
Email: akm@cellink.com

Monica Wellejus, Sales and Marketing Manager, Ossiform
Phone: +45 3175 0721
Email: mw@ossiform.com

About CELLINK

CELLINK is enabling the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.

About Ossiform

Ossiform is dedicated to improving the lives of people with bone defects. We provide patient-matched, natural, and resorbable bone implants to reduce complications, improve functional and aesthetic outcomes and obtain faster recovery. We are continuously working to redefine bone replacements through progressive research and close collaboration with physicians and industry partners. Our patient-centric approach and commitment to innovation, quality, and progress steer our efforts to provide best-in-class implant solutions that facilitate the natural forming of new bone. Ossiform’s unique bone printing technology is further used to provide customizable bone-mimetic constructs for enhancing bone and cancer research. In short: We Print Bone™.

Website: www.ossiform.com